However, we note that a trend can be observed wherein ER‐tumors that are positive for either the basal‐like expression markers (CK5/6 or EGFR positivity) or the Epi‐Basal markers (grouped together as “high‐risk non‐luminal”) are marginally associated with approximately 10‐fold increased risk for breast cancer‐specific death independently of the expression‐based definition for basal‐like cancers alone in a model with adjustment for age and year at diagnosis (Hazards ratio = 9.79; P = 0.079) (Figure 6C, lower panel). This evidence concerns the gene EGFR and breast cancer.